AU2530199A - Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods - Google Patents

Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods

Info

Publication number
AU2530199A
AU2530199A AU25301/99A AU2530199A AU2530199A AU 2530199 A AU2530199 A AU 2530199A AU 25301/99 A AU25301/99 A AU 25301/99A AU 2530199 A AU2530199 A AU 2530199A AU 2530199 A AU2530199 A AU 2530199A
Authority
AU
Australia
Prior art keywords
therapeutic
useful
methods
diagnostic compositions
immunoreagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU25301/99A
Inventor
Christopher Black
Daniel J Delecki
Chandra Shah
Henry Wolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Publication of AU2530199A publication Critical patent/AU2530199A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU25301/99A 1998-02-06 1999-02-08 Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods Withdrawn AU2530199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2023398A 1998-02-06 1998-02-06
US09020233 1998-02-06
PCT/GB1999/000396 WO1999039748A1 (en) 1998-02-06 1999-02-08 Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods

Publications (1)

Publication Number Publication Date
AU2530199A true AU2530199A (en) 1999-08-23

Family

ID=21797469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25301/99A Withdrawn AU2530199A (en) 1998-02-06 1999-02-08 Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods

Country Status (2)

Country Link
AU (1) AU2530199A (en)
WO (1) WO1999039748A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516316A (en) * 1999-10-06 2003-05-13 ファルマシア コーポレイション Uroganiline as an intestinal cancer inhibitor
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
FR2805994A1 (en) * 2000-03-10 2001-09-14 Agronomique Inst Nat Rech New compound for detecting and treating metastatic colorectal cancer comprises a conjugate of an STa peptide and an immunogenic protein which binds to the guanyl cyclase-c receptor
GB0105224D0 (en) 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
EP1389090A2 (en) * 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US8735360B2 (en) 2009-12-07 2014-05-27 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170804A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP6874266B2 (en) * 2017-09-22 2021-05-19 国立研究開発法人日本原子力研究開発機構 Method for Synthesis of Tetraalkyl Nitriloacetamide Diacetamide Compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
WO1995011694A1 (en) * 1993-10-26 1995-05-04 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
AU9452198A (en) * 1997-10-15 1999-05-17 Nycomed Imaging As Complexing agents and targeting immunoreagents

Also Published As

Publication number Publication date
WO1999039748A1 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
GB2331015B (en) Therapeutic methods and compositions involving isoflavones
AU2655599A (en) Endoluminal implant with therapeutic and diagnostic capability
AU3102097A (en) Spiro-piperidine derivatives and their use as therapeutic agents
AU5526399A (en) Improvements in or relating to the treatment of lesions
AU3762899A (en) Training dummy assembly in human form
AU1884797A (en) Improvements in or relating to contrast agents
AU4714797A (en) Improvements in or relating to contrast agents
AU2790199A (en) Biochemical compositions used in human treatment
AU9383098A (en) Novel targeted contrast agents for diagnostic and therapeutic use
AU6721598A (en) Dioxino derivatives and their use as therapeutic agents
AU3816697A (en) Conservin compositions and therapeutic and diagnostic uses therefor
AU715620C (en) Therapeutic methods and uses
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
AU4215399A (en) Dermatological compositions and methods
AU2530199A (en) Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
AU3472799A (en) Dermatological formulations and methods
AU2672795A (en) Benzopyrans and their use as therapeutic agents
AU3268197A (en) Spiro-piperidine derivatives and their use as therapeutic agents
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU6519899A (en) Improvements in and relating to emitters
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU1978397A (en) Urea nucleosides as therapeutic and diagnostic agents
AU5546898A (en) Human lysosomal sialidase and therapeutic uses thereof